Retroviruses are a family of viruses that cause a broad range of pathologies in animals and humans, from the apparently harmless, long-term genomic insertion of endogenous retroviruses, to tumors induced by the oncogenic retroviruses and acquired immunodeficiency syndrome (AIDS) resulting from human immunodeficiency virus infection. Disease can be the result of diverse mechanisms, including tumorigenesis induced by viral oncogenes or immune destruction, leading to the gradual loss of CD4 T-cells. Of the virally encoded proteins common to all retroviruses, the envelope (Env) displays perhaps the most diverse functionality. Env is primarily responsible for binding the cellular receptor and for effecting the fusion process, with these functions mediated by protein domains localized to the exterior of the virus. The remaining C-terminal domain may have the most variable functionality of all retroviral proteins. The C-terminal domains from three prototypical retroviruses are discussed, focusing on the different structures and functions, which include fusion activation, tumorigenesis and viral assembly and lifecycle influences. Despite these genetic and functional differences, however, the C-terminal domains of these viruses share a common feature in the modulation of Env ectodomain conformation. Despite their differences, perhaps each system still has information to share with the others.
References
[1]
Checkley, M.A.; Luttge, B.G.; Freed, E.O. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 2011, 410, 582–608, doi:10.1016/j.jmb.2011.04.042.
[2]
Haffar, O.K.; Dowbenko, D.J.; Berman, P.W. Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. J. Cell Biol. 1988, 107, 1677–1687, doi:10.1083/jcb.107.5.1677.
[3]
Hollier, M.J.; Dimmock, N.J. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: An analysis of sequence, structure, and function. Virology 2005, 337, 284–296, doi:10.1016/j.virol.2005.04.015.
[4]
Steckbeck, J.D.; Sun, C.; Sturgeon, T.J.; Montelaro, R.C. Detailed topology mapping reveals substantial exposure of the “cytoplasmic” C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface. PLoS One 2013, 8, e65220.
[5]
Steckbeck, J.D.; Sun, C.; Sturgeon, T.J.; Montelaro, R.C. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One 2010, 5, e15261.
[6]
Postler, T.S.; Martinez-Navio, J.M.; Yuste, E.; Desrosiers, R.C. Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J. Virol. 2012, 86, 1145–1157, doi:10.1128/JVI.06463-11.
Steckbeck, J.D.; Kuhlmann, A.-S.; Montelaro, R.C. C-terminal tail of human immunodeficiency virus gp41: Functionally rich and structurally enigmatic. J. Gen. Virol. 2013, 94, 1–19, doi:10.1099/vir.0.046508-0.
[9]
Postler, T.S.; Desrosiers, R.C. The tale of the long tail: The cytoplasmic domain of HIV-1 gp41. J. Virol. 2013, 87, 2–15, doi:10.1128/JVI.02053-12.
[10]
Da Silva, E.S.; Mulinge, M.; Bercoff, D.P. The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology 2013, 10, doi:10.1186/1742-4690-10-54.
Van der Putten, H.; Quint, W.; van Raaij, J.; Maandag, E.R.; Verma, I.M.; Berns, A. M-MuLV-induced leukemogenesis: Integration and structure of recombinant proviruses in tumors. Cell 1981, 24, 729–739, doi:10.1016/0092-8674(81)90099-4.
[13]
Green, N.; Shinnick, T.M.; Witte, O.; Ponticelli, A.; Sutcliffe, J.G.; Lerner, R.A. Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide. Proc. Natl. Acad. Sci. USA 1981, 78, 6023–6027, doi:10.1073/pnas.78.10.6023.
[14]
Ragheb, J.A.; Anderson, W.F. pH-Independent murine leukemia virus ecotropic envelope-mediated cell fusion: Implications for the role of the R peptide and p12E TM in viral entry. J. Virol. 1994, 68, 3220–3231.
[15]
Ragheb, J.A.; Anderson, W.F. Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: A functional analysis of the role of TM domains in viral entry. J. Virol. 1994, 68, 3207–3219.
[16]
Rein, A.; Mirro, J.; Haynes, J.G.; Ernst, S.M.; Nagashima, K. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E Cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J. Virol. 1994, 68, 1773–1781.
[17]
Yang, C.; Compans, R.W. Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: Inhibitory effects of the R peptide. J. Virol. 1996, 70, 248–254.
[18]
Li, M.; Li, Z.-N.; Yao, Q.; Yang, C.; Steinhauer, D.A.; Compans, R.W. Murine leukemia virus R peptide inhibits influenza virus hemagglutinin-induced membrane fusion. J. Virol. 2006, 80, 6106–6114, doi:10.1128/JVI.02665-05.
[19]
Yang, C.; Compans, R.W. Analysis of the murine leukemia virus R peptide: Delineation of the molecular determinants which are important for its fusion inhibition activity. J. Virol. 1997, 71, 8490–8496.
[20]
Li, M.; Yang, C.; Compans, R.W. Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide. J. Virol. 2001, 75, 2337–2344, doi:10.1128/JVI.75.5.2337-2344.2001.
[21]
L？ving, R.; Wu, S.-R.; Sj？berg, M.; Lindqvist, B.; Garoff, H. Maturation cleavage of the murine leukemia virus Env precursor separates the transmembrane subunits to prime it for receptor triggering. Proc. Natl. Acad. Sci. USA 2012, 109, 7735–7740.
[22]
Leroux, C.; Girard, N.; Cottin, V.; Greenland, T.; Mornex, J.-F.; Archer, F. Jaagsiekte Sheep Retrovirus (JSRV): From virus to lung cancer in sheep. Vet. Res. 2007, 38, 211–228, doi:10.1051/vetres:2006060.
[23]
Liu, S.-L.; Miller, A.D. Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein. Oncogene 2007, 26, 789–801, doi:10.1038/sj.onc.1209850.
[24]
Palmarini, M.; Fan, H. Molecular biology of jaagsiekte sheep retrovirus. Curr. Top. Microbiol. Immunol. 2003, 275, 81–115.
[25]
Rosati, S.; Pittau, M.; Alberti, A.; Pozzi, S.; York, D.F.; Sharp, J.M.; Palmarini, M. An accessory open reading frame (ORF-x) of jaagsiekte sheep retrovirus is conserved between different virus isolates. Virus Res. 2000, 66, 109–116, doi:10.1016/S0168-1702(99)00118-5.
[26]
Palmarini, M.; Sharp, J.M.; de las Heras, M.; Fan, H. Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep. J. Virol. 1999, 73, 6964–6972.
[27]
Wootton, S.K.; Halbert, C.L.; Miller, A.D. Sheep retrovirus structural protein induces lung tumours. Nature 2005, 434, 904–907, doi:10.1038/nature03492.
[28]
Caporale, M.; Cousens, C.; Centorame, P.; Pinoni, C.; de las Heras, M.; Palmarini, M. Expression of the jaagsiekte sheep retrovirus envelope glycoprotein is sufficient to induce lung tumors in sheep. J. Virol. 2006, 80, 8030–8037, doi:10.1128/JVI.00474-06.
[29]
Liu, S.-L.; Duh, F.-M.; Lerman, M.I.; Miller, A.D. Role of virus receptor Hyal2 in oncogenic transformation of rodent fibroblasts by sheep betaretrovirus env proteins. J. Virol. 2003, 77, 2850–2858, doi:10.1128/JVI.77.5.2850-2858.2003.
[30]
Danilkovitch-Miagkova, A.; Duh, F.-M.; Kuzmin, I.; Angeloni, D.; Liu, S.-L.; Miller, A.D.; Lerman, M.I. Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc. Natl. Acad. Sci. USA 2003, 100, 4580–4585, doi:10.1073/pnas.0837136100.
C？té, M.; Zheng, Y.-M.; Albritton, L.M.; Liu, S.-L. Fusogenicity of Jaagsiekte sheep retrovirus envelope protein is dependent on low pH and is enhanced by cytoplasmic tail truncations. J. Virol. 2008, 82, 2543–2554, doi:10.1128/JVI.01852-07.
[33]
Rushlow, K.; Olsen, K.; Stiegler, G.; Payne, S.L.; Montelaro, R.C.; Issel, C.J. Lentivirus genomic organization: The complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology 1986, 155, 309–321, doi:10.1016/0042-6822(86)90195-9.
[34]
Shacklett, B.L.; Weber, C.J.; Shaw, K.E.; Keddie, E.M.; Gardner, M.B.; Sonigo, P.; Luciw, P.A. The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J. Virol. 2000, 74, 5836–5844, doi:10.1128/JVI.74.13.5836-5844.2000.
[35]
Chakrabarti, L.; Emerman, M.; Tiollais, P.; Sonigo, P. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J. Virol. 1989, 63, 4395–4403.
[36]
Hirsch, V.M.; Edmondson, P.; Murphey-Corb, M.; Arbeille, B.; Johnson, P.R.; Mullins, J.I. SIV adaptation to human cells. Nature 1989, 341, 573–574, doi:10.1038/341573a0.
[37]
Kodama, T.; Wooley, D.P.; Naidu, Y.M.; Kestler, H.W.; Daniel, M.D.; Li, Y.; Desrosiers, R.C. Significance of premature stop codons in env of Simian immunodeficiency virus. J. Virol. 1989, 63, 4709–4714.
[38]
Eisenberg, D.; Wesson, M. The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41. Biopolymers 1990, 29, 171–177, doi:10.1002/bip.360290122.
[39]
Miller, M.A.; Garry, R.F.; Jaynes, J.M.; Montelaro, R.C. A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res. Hum. Retroviruses 1991, 7, 511–519, doi:10.1089/aid.1991.7.511.
[40]
Miller, M.A.; Cloyd, M.W.; Liebmann, J.; Rinaldo, C.R.; Islam, K.R.; Wang, S.Z.; Mietzner, T.A.; Montelaro, R.C. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993, 196, 89–100, doi:10.1006/viro.1993.1457.
[41]
Chernomordik, L.; Chanturiya, A.N.; Suss-Toby, E.; Nora, E.; Zimmerberg, J. An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J. Virol. 1994, 68, 7115–7123.
[42]
Kliger, Y.; Shai, Y. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 1997, 36, 5157–5169, doi:10.1021/bi962935r.
[43]
Srinivas, S.K.; Srinivas, R.V.; Anantharamaiah, G.M.; Segrest, J.P.; Compans, R.W. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J. Biol. Chem. 1992, 267, 7121–7127.
[44]
Steckbeck, J.D.; Craigo, J.K.; Barnes, C.O.; Montelaro, R.C. Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: Implications for functions in viral replication. J. Biol. Chem. 2011, 286, 27156–27166.
[45]
Boscia, A.L.; Akabori, K.; Benamram, Z.; Michel, J.A.; Jablin, M.S.; Steckbeck, J.D.; Montelaro, R.C.; Nagle, J.F.; Tristram-Nagle, S. Membrane Structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein. Biophys. J. 2013, 105, 657–666, doi:10.1016/j.bpj.2013.06.042.
[46]
Fujii, G.; Horvath, S.; Woodward, S.; Eiserling, F.; Eisenberg, D. A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41. Protein Sci. 1992, 1, 1454–1464, doi:10.1002/pro.5560011107.
[47]
Eisenberg, D.; Schwarz, E.; Komaromy, M.; Wall, R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 1984, 179, 125–142, doi:10.1016/0022-2836(84)90309-7.
[48]
Booth, P.; Templer, R.; Meijberg, W.; Allen, S.; Curran, A.; Lorch, M. In vitro studies of membrane protein folding. Crit. Rev. Biochem. Mol. Biol. 2001, 36, 501–603, doi:10.1080/20014091074246.
[49]
Cantor, R.S. Lateral pressures in cell membranes: A mechanism for modulation of protein function. J. Phys. Chem. 1997, 101, 1723–1725.
[50]
Cantor, R.S. Lipid composition and the lateral pressure profile in bilayers. Biophys. J. 1999, 76, 2625–2639, doi:10.1016/S0006-3495(99)77415-1.
[51]
Cantor, R.S. The influence of membrane lateral pressures on simple geometric models of protein conformational equilibria. Chem. Phys. Lipids 1999, 101, 45–56, doi:10.1016/S0009-3084(99)00054-7.
[52]
Tillman, T.S.; Cascio, M. Effects of membrane lipids on ion channel structure and function. Cell Biochem. Biophys. 2003, 38, 161–190, doi:10.1385/CBB:38:2:161.
[53]
Van den Brink-van der Laan, E.; Killian, J.A.; de Kruijff, B. Nonbilayer lipids affect peripheral and integral membrane proteins via changes in the lateral pressure profile. Biochim. Biophys. Acta 2004, 1666, 275–288, doi:10.1016/j.bbamem.2004.06.010.
[54]
Kalia, V.; Sarkar, S.; Gupta, P.; Montelaro, R.C. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J. Virol. 2005, 79, 2097–2107, doi:10.1128/JVI.79.4.2097-2107.2005.
[55]
Cantor, R.S. Size distribution of barrel-stave aggregates of membrane peptides: Influence of the bilayer lateral pressure profile. Biophys. J. 2002, 82, 2520–2525, doi:10.1016/S0006-3495(02)75595-1.
[56]
Marsh, D. Lateral pressure profile, spontaneous curvature frustration, and the incorporation and conformation of proteins in membranes. Biophys. J. 2007, 93, 3884–3899, doi:10.1529/biophysj.107.107938.
[57]
Joyner, A.S.; Willis, J.R.; Crowe, J.E.; Aiken, C. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog. 2011, 7, e1002234, doi:10.1371/journal.ppat.1002234.
[58]
White, T.A.; Bartesaghi, A.; Borgnia, M.J.; Meyerson, J.R.; de la Cruz, M.J.V.; Bess, J.W.; Nandwani, R.; Hoxie, J.A.; Lifson, J.D.; Milne, J.L.S.; et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: Strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6, e1001249, doi:10.1371/journal.ppat.1001249.
[59]
Lu, L.; Zhu, Y.; Huang, J.; Chen, X.; Yang, H.; Jiang, S.; Chen, Y.-H. Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: Interaction with gp41 fusion core. J. Biol. Chem. 2008, 283, 16723–16731.
[60]
Futaki, S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev. 2005, 57, 547–558, doi:10.1016/j.addr.2004.10.009.
[61]
Mitchell, D.J.; Kim, D.T.; Steinman, L.; Fathman, C.G.; Rothbard, J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 2000, 56, 318–325, doi:10.1034/j.1399-3011.2000.00723.x.
[62]
Tung, C.-H.; Weissleder, R. Arginine containing peptides as delivery vectors. Adv. Drug Deliv. Rev. 2003, 55, 281–294, doi:10.1016/S0169-409X(02)00183-7.
[63]
Inomata, K.; Ohno, A.; Tochio, H.; Isogai, S.; Tenno, T.; Nakase, I.; Takeuchi, T.; Futaki, S.; Ito, Y.; Hiroaki, H.; Shirakawa, M. High-resolution multi-dimensional NMR spectroscopy of proteins in human cells. Nature 2009, 458, 106–109, doi:10.1038/nature07839.
[64]
Freed, E.O.; Martin, M.A. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J. Virol. 1995, 69, 1984–1989.
[65]
Freed, E.O.; Martin, M.A. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 1996, 70, 341–351.
[66]
Jiang, J.; Aiken, C. Maturation-dependent HIV-1 Particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J. Virol. 2007, 81, 9999–10008, doi:10.1128/JVI.00592-07.
[67]
Murakami, T. Roles of the interactions between Env and Gag proteins in the HIV-1 replication cycle. Microbiol. Immunol. 2008, 52, 287–295, doi:10.1111/j.1348-0421.2008.00008.x.
[68]
Murakami, T.; Freed, E.O. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J. Virol. 2000, 74, 3548–3554, doi:10.1128/JVI.74.8.3548-3554.2000.
[69]
Murakami, T.; Freed, E.O. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl. Acad. Sci. USA 2000, 97, 343–348, doi:10.1073/pnas.97.1.343.
[70]
Kol, N.; Shi, Y.; Tsvitov, M.; Barlam, D.; Shneck, R.Z.; Kay, M.S.; Rousso, I. A stiffness switch in human immunodeficiency virus. Biophys. J. 2007, 92, 1777–1783, doi:10.1529/biophysj.106.093914.
[71]
Wyma, D.J.; Jiang, J.; Shi, J.; Zhou, J.; Lineberger, J.E.; Miller, M.D.; Aiken, C. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: A novel role of the gp41 cytoplasmic tail. J. Virol. 2004, 78, 3429–3435, doi:10.1128/JVI.78.7.3429-3435.2004.
[72]
Byland, R.; Vance, P.J.; Hoxie, J.A.; Marsh, M. A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol. Biol. Cell 2007, 18, 414–425.
[73]
Ohno, H.; Aguilar, R.C.; Fournier, M.C.; Hennecke, S.; Cosson, P.; Bonifacino, J.S. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 1997, 238, 305–315, doi:10.1006/viro.1997.8839.
[74]
Cosson, P. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J. 1996, 15, 5783–5788.
[75]
Schiavoni, I.; Trapp, S.; Santarcangelo, A.C.; Piacentini, V.; Pugliese, K.; Baur, A.; Federico, M. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity. J. Biol. Chem. 2004, 279, 22996–23006.
[76]
Sandrin, V.; Cosset, F.-L. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J. Biol. Chem. 2006, 281, 528–542, doi:10.1074/jbc.M506070200.
[77]
Wyma, D.J.; Kotov, A.; Aiken, C. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J. Virol. 2000, 74, 9381–9387, doi:10.1128/JVI.74.20.9381-9387.2000.
[78]
Kotov, A.; Zhou, J.; Flicker, P.; Aiken, C. Association of Nef with the human immunodeficiency virus type 1 core. J. Virol. 1999, 73, 8824–8830.
[79]
Boge, M.; Wyss, S.; Bonifacino, J.S.; Thali, M. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 1998, 273, 15773–15778, doi:10.1074/jbc.273.25.15773.
[80]
Miller, M.A.; Mietzner, T.A.; Cloyd, M.W.; Robey, W.G.; Montelaro, R.C. Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res. Hum. Retroviruses 1993, 9, 1057–1066, doi:10.1089/aid.1993.9.1057.
[81]
Tencza, S.B.; Miller, M.A.; Islam, K.; Mietzner, T.A.; Montelaro, R.C. Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. J. Virol. 1995, 69, 5199–5202.
[82]
Zhang, H.; Wang, L.; Kao, S.; Whitehead, I.P.; Hart, M.J.; Liu, B.; Duus, K.; Burridge, K.; Der, C.J.; Su, L. Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr. Biol. 1999, 9, 1271–1274, doi:10.1016/S0960-9822(99)80511-9.
[83]
Wang, L.; Zhang, H.; Solski, P.A.; Hart, M.J.; Der, C.J.; Su, L. Modulation of HIV-1 replication by a novel RhoA effector activity. J. Immunol. 2000, 164, 5369–5374.
[84]
Blot, G.; Lopez-Vergès, S.; Treand, C.; Kubat, N.J.; Delcroix-Genête, D.; Emiliani, S.; Benarous, R.; Berlioz-Torrent, C. Luman, a new partner of HIV-1 TMgp41, interferes with Tat-mediated transcription of the HIV-1 LTR. J. Mol. Biol. 2006, 364, 1034–1047, doi:10.1016/j.jmb.2006.09.080.
[85]
Emerson, V.; Haller, C.; Pfeiffer, T.; Fackler, O.T.; Bosch, V. Role of the C-terminal domain of the HIV-1 glycoprotein in cell-to-cell viral transmission between T lymphocytes. Retrovirology 2010, 7, doi:10.1186/1742-4690-7-43.
[86]
Mishra, S.; Murphy, L.C.; Murphy, L.J. The Prohibitins: Emerging roles in diverse functions. J. Cell. Mol. Med. 2006, 10, 353–363, doi:10.1111/j.1582-4934.2006.tb00404.x.
[87]
Mishra, S.; Ande, S.R.; Nyomba, B.L.G. The role of prohibitin in cell signaling. FEBS J. 2010, 277, 3937–3946, doi:10.1111/j.1742-4658.2010.07809.x.
[88]
Postler, T.S.; Desrosiers, R.C. The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1. Cell Host Microbe 2012, 11, 181–193, doi:10.1016/j.chom.2011.12.005.
[89]
Edinger, A.L.; Mankowski, J.L.; Doranz, B.J.; Margulies, B.J.; Lee, B.; Rucker, J.; Sharron, M.; Hoffman, T.L.; Berson, J.F.; Zink, M.C.; et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc. Natl. Acad. Sci. USA 1997, 94, 14742–14747, doi:10.1073/pnas.94.26.14742.
[90]
Edwards, T.G.; Wyss, S.; Reeves, J.D.; Zolla-Pazner, S.; Hoxie, J.A.; Doms, R.W.; Baribaud, F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 2002, 76, 2683–2691, doi:10.1128/JVI.76.6.2683-2691.2002.
[91]
Kalia, V.; Sarkar, S.; Gupta, P.; Montelaro, R.C. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation. J. Virol. 2003, 77, 3634–3646, doi:10.1128/JVI.77.6.3634-3646.2003.
